Intermittent Theta Burst Stimulation (iTBS) for the Treatment of Negative Symptoms in Schizophrenia
NCT ID: NCT00875498
Last Updated: 2016-01-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
22 participants
INTERVENTIONAL
2008-11-30
2015-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
iTBS on Negative Symptoms and Cognitive Function in Schizophrenia
NCT05137158
Effect of Intermittent Theta Burst Stimulation (iTBS) for Alleviating Symptoms of Schizophrenia Patients
NCT03868358
Effect of Intermittent ThetaBurst Stimulation in Treatment-resistant Bipolar Depression
NCT02740244
Personalized iTBS in Real-World Clinical Settings for Schizophrenia
NCT07176468
Repetitive Transcranial Magnetic Stimulation and Intermittent Theta Burst (iTBS) in Schizophrenia
NCT01315587
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Neuroimaging studies demonstrate that hypoactivity in the left dorsolateral prefrontal cortex (LDLPFC) was associated with negative symptoms.
The investigators hypothesize that iTBS applied to LDLPFC will improve negative symptoms and will improve activity of the LDLPFC measured with Magnetic Resonance Spectroscopy (MRS).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
active iTBS
iTBS active intensity = 80%MT during 6 minutes. 20 sessions, 2 per day
active iTBS
Intermittent Theta Burst Stimulation (iTBS) over Left dorsolateral prefrontal cortex.
80% MT, 20 sessions of 6 minutes, 2 per day
sham iTBS
iTBS placebo (placebo coil)with same parameters than active
sham iTBS
iTBS placebo (placebo coil)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
active iTBS
Intermittent Theta Burst Stimulation (iTBS) over Left dorsolateral prefrontal cortex.
80% MT, 20 sessions of 6 minutes, 2 per day
sham iTBS
iTBS placebo (placebo coil)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Negative symptoms for at least 6 weeks
* Medication resistance according to Kane et al., 1988
* Age between 18 and 50 years old
* Informed consent
Exclusion Criteria
* Pregnancy
18 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hôpital le Vinatier
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. E. Poulet
PUPH
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Emmanuel Poulet, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Hopital Le Vinatier
JEROME BRUNELIN, PhD
Role: STUDY_DIRECTOR
Hopital le Vinatier
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hopital Le vinatier
Bron, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2008-A00558-47
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.